- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- AZD9668, AZD9668 Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Fullerton, California • Valparaiso, Indiana • Council Bluffs, Iowa + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 868
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypotension, Pain
- Interventions
- Ropivacaine, Epinephrine
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Venous Leg Ulcer, Venous Stasis Ulcers
- Interventions
- HP802-247, Placebo (Vehicle)
- Biological
- Lead sponsor
- Healthpoint
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more
- Conditions
- Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
- Interventions
- bremelanotide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
- Conditions
- Multiple Sclerosis
- Interventions
- ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
- Conditions
- Treatment Resistant Depression
- Interventions
- BPL-003
- Drug
- Lead sponsor
- Beckley Psytech Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • San Diego, California + 15 more
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
- Interventions
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Disease
- Interventions
- Olpasiran, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Boca Raton, Florida • Atlanta, Georgia + 7 more
- Conditions
- Gastrointestinal Dysmotility
- Interventions
- Saline Solution for Injection, Ipamorelin
- Drug
- Lead sponsor
- Helsinn Therapeutics (U.S.), Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 45
- States / cities
- Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
- Conditions
- Myelofibrosis
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 3
- States / cities
- Winter Park, Florida • Baltimore, Maryland • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- CC-220, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more
- Conditions
- Geographic Atrophy
- Interventions
- STL303, Placebo
- Drug
- Lead sponsor
- Sitala Bio LTD
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 16
- States / cities
- Bakersfield, California • Beverly Hills, California • Aurora, Colorado + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- The Bronx, New York • San Antonio, Texas
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Interventions
- CC-90009
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 6
- States / cities
- Stanford, California • New Haven, Connecticut • Chicago, Illinois + 3 more
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Interventions
- Tempol, Placebo Solution
- Drug
- Lead sponsor
- Matrix Biomed, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- La Jolla, California • Merced, California • San Francisco, California + 4 more
- Conditions
- Type 1 Diabetes
- Interventions
- Acetazolamide
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Depression
- Interventions
- Trigeminal Nerve Stimulation
- Procedure
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neoplasms
- Interventions
- BI 905677
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Interventions
- CC-90002
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
- Conditions
- Hypercholesterolaemia
- Interventions
- alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
- Conditions
- NON-breast HER2+ Malignancies
- Interventions
- NJH395
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Medication Adherence
- Interventions
- 5 Behavioral Change Techniques
- Behavioral
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mucopolysaccharidosis I
- Interventions
- AGT-181 (HIRMAb-IDUA)
- Drug
- Lead sponsor
- ArmaGen, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Oakland, California • Orange, California • Decatur, Georgia + 3 more
- Conditions
- Weight Loss
- Interventions
- Placebo, VK2735
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more